Why the study?
Does adjuvant chemotherapy increase the incidence of brain metastases as a site of first recurrence in patients with node-positive operable breast carcinoma compared to local measures only?
Does adjuvant chemotherapy increase the incidence of brain metastases as a site of first recurrence in patients with node-positive operable breast carcinoma compared to local measures only?
Adjuvant chemotherapy in node-positive operable breast cancer may be associated with an increased incidence of brain metastases as the first site of recurrence, likely due to prolonged systemic disease suppression without adequate CNS control.
Answers are grounded in this paper and cite their sources.
May suggest increased brain metastasis risk with adjuvant chemotherapy; hypothesis-generating and should not change practice without randomized confirmation.
A retrospective analysis was performed comparing the incidence of brain metastases as a site of first recurrence in patients receiving adjuvant chemotherapy during the period from 1973--1979 for node-positive operable carcinoma of the breast, compared to a matched control group of patients presenting during the same period treated by local measures only. Five of 115 patients (4.3%) receiving adjuvant chemotherapy have had brain metastases as first site of distant recurrence compared to zero of 115 (0%) in the control group. This comprised 12.8% of first distant recurrences in the adjuvant group. The authors suggest that this increased incidence of brain metastases, as site of first recurrence, reflects prolonged suppression of systemic disease by adjuvant chemotherapy with less effect in controlling metastases in the brain.
No takes yet. Share an insight, caveat, or question.
Paterson et al. (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: